| abstract |
Provided are compounds that modulate glucagon-like peptide 1 (GLP-1) receptors, as well as methods for synthesizing them, and methods for their therapeutic and / or prophylactic uses. Such compounds can be used alone or in combination with incretin peptides such as GLP-1 (7-36) and GLP-1 (9-36) or with peptide-based therapeutic agents such as exenatide and liraglutide. It can act as a modulator or enhancer of the GLP-1 receptor and has the general structure Represents one or both of the R and S forms of this compound) (I): Where A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are defined herein As defined. |